5-HT 2A/C receptors mediate the antipsychotic-like effects of alstonine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 36, Issue 1, 2012, Pages 29-33

  Linck, V M ^a   Bessa, M M ^a   Herrmann, A P ^a   Iwu, M M ^b   Okunji, C O ^b   Elisabetsky, E ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b International Centre for Ethno Medicine and Drug Discovery (InterCEDD)   (Nigeria)

Author keywords

5 HT 2A C receptors; Alstonine; Antipsychotics; Working memory

Indexed keywords

ALSTONINE; DIZOCILPINE; INDOLE ALKALOID; NEUROLEPTIC AGENT; RITANSERIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; DIZOCILPINE MALEATE; RAUWOLFIA ALKALOID; SERPENTINE (ALKALOID);

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT RESPONSE; WORKING MEMORY; ANIMAL; CHEMICALLY INDUCED DISORDER; HYPERKINESIA; MEMORY DISORDER; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; HYPERKINESIS; MALE; MEMORY DISORDERS; MICE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; SECOLOGANIN TRYPTAMINE ALKALOIDS;

EID: 82555197925     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.08.022     Document Type: Article

References (38)

1. Anil Yaǧcioǧlu A. The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment?. Turk Psikiyatri Derg 2007, 18:364-374.
2. Barch D. The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 2005, 1:321-353.
3. Barros D., Ramirez M., Izquierdo I. Modulation of working, short- and long-term memory by nicotinic receptors in the basolateral amygdala in rats. Neurobiol Learn Mem 2005, 83:113-118.
4. Belforte J., Zsiros V., Sklar E., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
5. Bianchin M., Mello e Souza T., Medina J.H., Izquierdo I. The amygdala is involved in the modulation of long-term memory, but not in working or short-term memory. Neurobiol Learn Mem 1999, 71:127-131.
6. Costa-Campos L., Lara D., Nunes D., Elisabetsky E. Antipsychotic-like profile of alstonine. Pharmacol Biochem Behav 1998, 60:133-141.
7. Costa-Campos L., Dassoler S., Rigo A., Iwu M., Elisabetsky E. Anxiolytic properties of the antipsychotic alkaloid alstonine. Pharmacol Biochem Behav 2004, 77:481-489.
8. de Moura Linck V., Herrmann A., Goerck G., Iwu M., Okunji C., Leal M., et al. The putative antipsychotic alstonine reverses social interaction withdrawal in mice. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32.
9. Elisabetsky E. Phytotherapy and the new paradigm of drugs mode of action. Rev Prod Nat 2007, XII:159-164.
10. Elisabetsky E., Costa-Campos L. The alkaloid alstonine: a review of its pharmacological properties. Evid Based Complement Alternat Med 2006, 3:39-48.
11. Gründer G., Hippius H., Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009, 8:197-202.
12. Hamann J., Leucht S., Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003, 36:18-26.
13. Harvey P. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev 2009, 19:324-335.
14. Hyman S.E., Fenton W.S. Medicine. What are the right targets for psychopharmacology?. Science 2003, 299:350-351.
15. Insel T.R. Rethinking schizophrenia. Nature 2010, 468:187-193.
16. Javitt D.C. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci 2010, 7:4-16.
17. Keefe R., Fenton W. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr Bull 2007, 33:912-920.
18. Keefe R., Bilder R., Davis S., Harvey P., Palmer B., Gold J., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647.
19. Kristiansen L., Huerta I., Beneyto M., Meador-Woodruff J. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007, 7:48-55.
20. Labonte B., Bambico F.R., Gobbi G. Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:383-397.
21. Large C.H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?. J Psychopharmacol 2007, 21:283-301.
22. Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier?. Science 2009, 325:161-165.
23. Lieberman J., Stroup T., McEvoy J., Swartz M., Rosenheck R., Perkins D., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
24. Linck V.M., Herrmann A.P., Piato A.L., Detanico B.C., Figueiró M., Florio J.C., Iwu M.M., Okunji C.O., Leal M.B., Elisabetsky E. Alstonine as an antipsychotic: Effects on brain amines and metabolic changes. Evidence-Based Complementary and Alternative Medicine (Print) 2011, 2011:1-7.
25. López-Gil X., Babot Z., Amargós-Bosch M., Suñol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097.
26. Martin P., Carlsson M., Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998, 9:2985-2988.
27. Meltzer H., Massey B. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 2011, 11:59-67.
28. Ninan I., Kulkarni S. 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion. Eur J Pharmacol 1998, 358:111-116.
29. Okunji C.O., Iwu M.M., Ito Y. Preparative separation of indole alkaloids from the rind of Picralima nitida (Stapf) T. Durand & H. Durand by pH-Zone-refining countercurrent chromatography. J Liq Chromatogr Relat Technol 2005, 28:775-783.
30. Okunji C.O., Awachie P.I., Iwu M.M., Tchimene M., Knight M., Ito Y. Preparative separation of picralima alkaloids using a new flat-twisted tubing in pH-zone-refining countercurrent chromatography mode. Planta Med 2011, 77(5):P-101.
31. Patwardhan B. Ethnopharmacology and drug discovery. J Ethnopharmacol 2005, 100:50-52.
32. Paz R.D., Tardito S., Atzori M., Tseng K.Y. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008, 18:773-786.
33. Rujescu D., Bender A., Keck M., Hartmann A., Ohl F., Raeder H., et al. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 2006, 59:721-729.
34. Rung J., Carlsson A., Rydén Markinhuhta K., Carlsson M. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:827-832.
35. Shinomiya K., Menet J.M., Fales H.M., Ito Y. Studies on a new cross-axis coil planet centrifuge for performing countercurrent chromatography. 1. Design of the apparatus, retention of the stationary-phase, and efficiency in the separation of proteins with polymer phase systems. J Chromatogr 1993, 644:215-229.
36. Silver H., Feldman P., Bilker W., Gur R. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003, 160:1809-1816.
37. 2A/2C receptors. Eur J Pharmacol 2007, 564:123-130.
38. Wykes T., Newton E., Landau S., Rice C., Thompson N., Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res 2007, 94:221-230.